Genmab A (GMAB) earnings: date, estimates and history
Price $51.37 · data as of November 13, 2026
Next earnings report
The date appears here once Genmab A confirms it, usually two to four weeks before the report.
Track record
Genmab A beat the consensus earnings estimate in 3 of its last 4 reports, by +32.6% on average. On report days the stock moved 4.1% on average, up or down.
Earnings history
| Reported | EPS estimate | EPS actual | Surprise | Revenue | Revenue growth | Stock move |
|---|---|---|---|---|---|---|
| November 5, 2026 Sep/2026 | $0.32 | $0.55 | +70.5% | — | — | −2.7% |
| August 6, 2026 Jun/2026 | $0.33 | $0.49 | +47.5% | — | — | +6.8% |
| May 7, 2026 Mar/2026 | $0.19 | $0.13 | −29.7% | — | — | −5.2% |
| November 6, 2025 Sep/2025 | $0.45 | $0.65 | +42.3% | — | — | −1.8% |
EPS as compared with analyst estimates (adjusted EPS). Revenue growth is against the same quarter a year earlier. Stock move: change on the first trading day after the report.
Frequently asked questions
When is Genmab A’s next earnings date?
Genmab A has not confirmed its next report date yet. Its last report was on November 5, 2026.
Did Genmab A beat earnings last quarter?
Yes, it reported EPS of $0.55 on November 5, 2026 against an estimate of $0.32 (a +70.5% surprise), and the stock moved −2.7% the next trading day.
What EPS do analysts expect next quarter?
The consensus estimate is $0.20 per share on revenue of about $8.4B.
Report dates and estimates from analyst consensus data; results from company reports. Updated daily. Not investment advice. Earnings calendar